sb 203580 has been researched along with thiacremonone in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (thiacremonone) | Trials (thiacremonone) | Recent Studies (post-2010) (thiacremonone) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 10 | 0 | 7 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Choi, DY; Han, SB; Hong, JT; Hwang, CJ; Hwang, DY; Jeong, HS; Kim, SY; Kim, TH; Kim, YM; Lee, HJ; Lee, HP; Lee, TH; Moon, DB; Oh, KW; Park, SS | 1 |
1 other study(ies) available for sb 203580 and thiacremonone
Article | Year |
---|---|
Inhibitory effect of thiacremonone on MPTP-induced dopaminergic neurodegeneration through inhibition of p38 activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Astrocytes; Behavioral Symptoms; Cell Line; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Humans; Imidazoles; Inflammation; Male; Mice; Mice, Inbred ICR; Microglia; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Pyridines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiophenes | 2016 |